Blood samples were obtained from 66 of the 67 factory workers, including the administrative employees. Serologic testing was carried out at 2 time points (December 2006 and December 2007) by using a commercial ELISA (Serion, Würzburg, Germany) based on plates coated with purified anthrax protective antigen (PA) (Technical Appendix). The first year, 3 workers had immunoglobulin (Ig) G titers above the threshold recommended by the manufacturer for vaccine protection (>15 IU/mL), and titers for another worker were considered borderline (10–15 IU/mL). All 4 workers had positive results by Western blot or dot blot analysis with pure recombinant anthrax PA and lethal factor (LF). One year later, 54 workers were sampled (2 were new employees). The second round of testing gave similar results, except for 3 additional borderline cases which could also be confirmed by Western blot/dot blot analysis (Table). Lymphocyte proliferation assays were performed concurrently by using fresh, heparinized, whole blood samples to evaluate the cell-mediated immunity of the workers (9). This technique measures the ability of lymphocytes placed in short-term tissue culture to undergo clonal proliferation when stimulated in vitro by a foreign antigen. Cell proliferation was determined by measuring the incorporation of ³H-thymidine into chromosomal DNA. The release of interferon-gamma (IFN-γ) in the course of lymphocyte stimulation was also measured to assess antigen-specific, cell-mediated reactivity. The antigens used here were pure recombinant PA and LF, along with positive control (concanavalin A) and negative control (phosphate buffer) stimulants. As shown in the Table, 2 cultures were positive in proliferation assays. Of these 2 cultures, 1 reacted with PA and LF, and 1 reacted with PA only. When added together, PA and LF suppressed the proliferative effect of the individual antigens, consecutive to the probable cytotoxicity induced by the 2 assembled antigens (porin + toxin). Typical examples of lymphocyte proliferation results are shown in Figure 1. The lymphocyte cultures found to be responsive to pure anthrax antigens originated from workers who had little circulating anti-PA IgG (<15 IU/mL), as tested by ELISA (Figure 2). However, their serum tested positive by Western blot analysis (Table). Moreover, supernatants of PA-stimulated lymphocyte cultures derived from the blood of these workers with positive results by determining counts per minute, were confirmed by IFN-γ release assay.

Although some progress made in improving the biologic safety of the industrial processing of wool and goat hair (for example, systematic disinfection, air filtering, and protective gear for employees working in closed areas), this study shows that B. anthracis still poses a health risk to modern wool workers. Handling nondisinfected, raw animal fibers from areas where anthrax is endemic, such as the southern Caucasus region and the Middle East, has been and remains an at-risk activity. The presence of circulating antibodies and T lymphocytes that react with antigens expressed only by vegetative cells of B. anthracis in unvaccinated wool workers confirms several previous findings. First, these findings support the conclusions that anthrax spores are able to germinate into vegetative cells at the sites of exposure (skin, mucosa, respiratory tract) and cause asymptomatic infection (10,11). Second, the extent to which the human immune system responds to exposure to anthrax spores from the surrounding environment as well as the nature of this response varies tremendously from person to person. This conclusion was well exemplified by the situations of 2 workers. Results from 1 worker (T29) displayed a high IgG titer (>100 U/mL) but little or no cell-mediated reactivity. Results from the other worker (T2) showed significant lymphocyte reactivity (³H-thymidine counts >700 counts per minute, which corresponds to a proliferative index of 6, p>0.01), but a low IgG titer (Figure 2), which reflects reciprocal T- and B-cell responses. None of the persons whose samples tested positive by ELISA reported a past episode of anthrax (according to face-to-face interviews conducted when blood was sampled). Hence, their seroconversion most likely resulted from asymptomatic B. anthracis infection. One worker reported having had a skin lesion possibly compatible with cutaneous anthrax 4 years before the study. That worker’s samples tested positive by lymphocyte proliferation assay, Western blot, and dot blot, but not by anti-PA ELISA.

Notably, samples from many workers from the same factory, who had been exposed to goat hair for years in similar conditions, did not display positive serologic results when tested by ELISA. During our study, however, we noticed that serum samples from 3 workers had seroconverted from negative to partially protective (borderline) IgG titers at some point between the 2 blood samplings as determined by anti-PA ELISA. Given the long history of these workers at the company, the apparent lack of anti-PA antibodies at the first blood sampling may have been misestimated due to the high threshold defined for seropositivity by the commercial ELISA used in the study. This commercial kit is indeed primarily aimed at evaluating the efficacy of anthrax vaccination rather than at detecting antibody responses after exposure to subinfectious doses of anthrax spores (12). Accordingly, we noticed that of the 3 workers who seroconverted, 2 tested positive by Western blot, and 1 tested positive by dot blot when tested retrospectively at year 1. Blotting techniques seem thus more sensitive than the presently used ELISA seropositivity threshold for detecting low anti-PA antibody titers. The low sensitivity of the method used in this work to assess cell-mediated immunity (whole blood proliferation assay) may have also underestimated the actual number of workers who exhibited cell-mediated immunity against B. anthracis, and the results should be regarded as indicative rather than representative.

PA-based anthrax vaccines are available to protect professionally exposed people, such as the US anthrax vaccine adsorbed or the UK anthrax vaccine. These vaccines are efficient and elicit humoral responses that protect the vaccinees against toxin-associated death (13). They do require long clinical protocols and yearly boosters (14) and are not officially licensed in European Union member states (except the United Kingdom). According to some authors, these vaccines might not protect wool-workers efficiently against subclinical infection, spore germination, or bacteremia (13,15). Anthrax vaccines that confer long-term immunity of both the humoral and cellular type are not yet available for the general public. Vaccines with such characteristics would be highly desirable to better protect persons who work with animal products that are possibly contaminated with anthrax spores.